
The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

The original STAR*D authors refute claims of a violated protocol.

H. Steven Moffic, MD, views the Dune book and movies through a psychiatric lens.

Contesters of STAR*D discuss the impact and relevance of the study's remission rates.

"For we are a healing and a growing greenhouse..."

The therapy is the first self-neuromodulation device for PTSD approved by the US Food and Drug Administration.

This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared with intravenous DMT for treatment-resistant depression.

What are your top 3 ethics issues? Take our survey!

STAR*D trial is one of the most important foundational studies in psychiatry to guide the treatment of unipolar major depression. Get ready to explore a dialogue between the original STAR*D authors and a group of authors who call STAR*D into question.

Remembering the 1-year anniversary of Frank Miller, MD’s death.
